Bioorganic Chemistry (2020)
Update date:2022-08-16
Topics:
Abd El-Khalek, Rofida
Abo El-Maali, Nagwa
Badr, Gamal
El-Kashef, Hussein
Lebegue, Nicolas
Melnyk, Patricia
Sayed, Douaa
A novel series of (Z)-3,5-disubstituted thiazolidine-2,4-diones 4–16 has been designed and synthesized. Preliminary screening of these compounds for their anti-breast cancer activity revealed that compounds 5, 7, and 9 possess the highest anti-cancer activities. The anti-tumor effects of compounds 5, 7, and 9 were evaluated against human breast cancer cell lines (MCF-7 and MDA-MB-231) and human breast cancer cells. They were also evaluated against normal non-cancerous breast cells, isolated from the same patients, to conclude about their use in a potential targeted therapy. Using MTT uptake method, these three compounds 5, 7, and 9 blunt the proliferation of these cancer cells in a dose-dependent manner with an IC50 of 1.27, 1.50 and 1.31 μM respectively. Interestingly, using flow cytometry analysis these three compounds significantly mediated apoptosis of human breast cancer cells without affecting the survival of normal non-cancerous breast cells that were isolated from the same patients. Mechanistically, these compounds blunt the proliferation of MCF-7 breast cancer cells by robustly decreasing the phosphorylation of AKT, mTOR and the expression of VEGF and HIF-1α. Most importantly, compounds 5, 7, and 9 without affecting the phosphorylation and expression of these crucial cellular factors in normal non-cancerous breast cells that were isolated from the same patients. Additionally, using Western blot analysis the three compounds significantly (P < 0.05) decreased the expression of the anti-apoptotic Bcl-2 members (Bcl-2, Bcl-XL and Mcl-1) and increased the expression of the pro-apoptotic Bcl-2 members (Bak, Bax and Bim) in MCF-7, MDA-MB-231 and human breast cancer cells making these breast cancer cells susceptible for apoptosis induction. Taken together, these data provide great evidences for the inhibitory activity of these compounds against breast cancer cells without affecting the normal breast cells.
View MoreJiangsu Zenji Pharmaceuticals LTD
Contact:+86-025-83172562; +1-224-888-1133(USA)
Address:No.5 Xinmofan Road
Fuxin Jintelai Fluorin Chemical Co., Ltd.
Contact:+86-0418-8229599
Address:, 7th Huagong Road, Fluorine industry development zone (Yimatu Town,Fumeng County),Fuxin City, Liaoning Province, China
Jiangsu Taihu New Materials Holding Co., Ltd
Contact:+86-519-86160108
Address:Xueyan Town, Changzhou City, Jiangsu Province, 213169, China
Evergreen Chemical Industry Ltd.
Contact:86-553-4918210
Address:6#2-602 Wanhaobailing
Contact:+86-371-55981030
Address:Room 1571, Macalline Soho, No.1, Shangdu Road, Zhengzhou, Henan
Doi:10.1002/poc.3423
(2015)Doi:10.1016/S0957-4166(01)00433-5
(2001)Doi:10.1039/b926068d
(2010)Doi:10.1016/S0223-5234(00)80029-X
(1999)Doi:10.1039/b908392h
(2009)Doi:10.1039/c7cc05160c
(2017)